Teladoc (TDOC) Form 144 Notice — 3,998 Shares from Restricted Vesting

Rhea-AI Filing Summary

Form 144 filed for Teladoc Health, Inc. (TDOC) by a selling person reporting a proposed sale of 3,998 shares of common stock through Fidelity Brokerage Services on the NYSE with an aggregate market value of $30,326.03. The filer states the shares were acquired on 08/29/2025 via restricted stock vesting as compensation and that payment was completed on that date. The notice lists one sale in the prior three months: 3,958 shares sold on 06/02/2025 for $27,151.88. The signer certifies no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice for a small block of vested shares; not materially impactful to shareholders.

The Form 144 documents a proposed sale of 3,998 vested shares by an insider through a broker on the NYSE, valued at $30,326.03. The filing also discloses a recent prior sale of 3,958 shares generating $27,151.88. This is a disclosure and procedural compliance with Rule 144 rather than a signal of company-level financial stress. The transaction stems from restricted stock vesting and was paid as compensation, consistent with executive or employee equity compensation policies.

Corporate Governance Expert

TL;DR: Compliance-focused filing that confirms insider is meeting disclosure obligations after restricted stock vesting.

The notice confirms the seller represented there is no undisclosed material adverse information and indicates the sale will be executed through a registered broker. Documentation of acquisition date and nature (restricted stock vesting) aligns with standard equity compensation practices. There is no indication of accelerated or unusual disposal patterns beyond a routine recent sale disclosed for the prior three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3998	30326.03	176690662	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			3998	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Carlos Nueno 155 E 44th Street, Floor 17 New York NY 10017	Common	06/02/2025	3958	27151.88

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Teladoc (TDOC) Form 144 filed here disclose?

The filing discloses a proposed sale of 3,998 common shares via Fidelity on the NYSE with an aggregate market value of $30,326.03.

How were the shares acquired that are being sold in the TDOC Form 144?

The shares were acquired on 08/29/2025 through restricted stock vesting and the payment nature is listed as compensation.

Did the filer sell other Teladoc shares recently?

Yes. The filing reports a sale during the past three months of 3,958 shares on 06/02/2025 for $27,151.88.

Through which broker will the TDOC shares be sold?

The proposed sale lists Fidelity Brokerage Services LLC (address provided) as the broker and names the exchange as NYSE.

Does the Form 144 indicate undisclosed material information about Teladoc?

No. The signer represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.